Direct Detection of Cancer Biomarker in Physiological Salt Concentration for FET based Biosensors

直接測量生理鹽環境中癌症生物標記的FET生物感測器

銘月(Indu)

指導教授 ： 王玉麟 ； 陳致真

國立清華大學/工學院/奈米工程與微系統研究所/碩士(2015年)

摘要

Cancer claims millions of human lives every year. Delayed diagnosis and inefficient prognostic tools lead to high mortality rate. Cancer biomarkers can provide molecular based information that can be used as a supplementary tool by doctors in effective prognosis after surgery or even early stage cancer detection. Our focus is to develop a microelectronic sensor that can detect cancer biomarker, which can be used by physicians to direct patients towards right prognosis. For achieving this, AlGaN/GaN High Electron Mobility Transistor (HEMT) has been used as an Immuno-FET, in which one of the common cancer biomarkers, CEA has been used as the target protein to bind with its antibody. Traditional FET-based sensors have the limitation set by electrostatic screening effect, hindering target detection in physiological salt concentration. Complicated sample pre-treatment methods are often employed prior to detection. Our sensor design can overcome this limitation by immobilizing the receptor on the in plane gate electrode and applying a short duration pulse at the gate. The capacitive type of current obtained from HEMT, can provide us useful information and can depict dynamic mode of measurement. This method of measurement, combined with the high sensitivity of AlGaN/GaN HEMT can overcome the drawbacks of traditional FETs and offer better limit of detection, sensitivity, repeatability and convenience.

關鍵字

直接測量生理鹽環境中癌症生物標記的FET生物感測器

並列摘要

無資料

並列關鍵字

FET based biosensors ； Cancer Biomarker ； AlGaN/GaN HEMT

參考文獻

[1] M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, et al., "Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing," New England Journal of Medicine, vol. 366, pp. 883-892, 2012.

[2] M. Verma and U. Manne, "Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations," Critical Reviews in Oncology/Hematology, vol. 60, pp. 9-18, 2006.

[3] P. P. Leong, W. M. Koch, A. Reed, D. Eisele, D. Sidransky, J. Jen, et al., "Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Sauamous Cell Carcinoma," Journal of the National Cancer Institute, vol. 90, pp. 972-977, 1998.

[4] J. S. Choi and J. S. Min, "Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients," Yonsei Med J, vol. 38, pp. 1-7, 1997.

[5] C. L. Sawyers, "The cancer biomarker problem," Nature, vol. 452, pp. 548-552, 2008.